生物标记物在弥漫胶质瘤中的应用(3)
參考文献：
[1]Louis D N，Perry A，Reifenberger G，et al.The 2016 World Health Organization Classification of Tumors of the Central Nervous System：a summary[J].Acta Neuropathologica，2016，131(6)：803-820.
[2]Louis DN，Perry A，Burger P，et al.International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading[J].Brain Pathology，2014，24(5)：429-435.
[3]Cohen AL，Holmen SL，Colman H.IDH1 and IDH2 mutations in gliomas[J].Current Neurology&Neuroscience Reports，2013，13(5)：345.
, http://www.100md.com
[4]Appin CL，Brat DJ.Biomarker-driven diagnosis of diffuse gliomas[J].Molecular Aspects of Medicine，2015(45)：87-96.
[5]Van den Bent MJ，Dubbink HJ，Marie Y，et al.IDH1 and mutations are prognostic but not predictive for outcome in anaplastic oligodendmglial tumors：A report of the european organization for research and treatment of cancer brain tumor group[J]. Clinical Cancer Research，2010(16)：1597-1604.
[6]Metellus P，Coulibaly B，Colin C，et al.Absence of IDH mutation identifies a novel radiologic and molecular subtype of who gradeⅡ gliomas with dismal prognosis[J].Acta Neuropathologica，2010(120)：719-729.
, 百拇医药
[7]Hartmann C，Meyer J，Balss J，et al.Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age：a study of 1010 diffuse gliomas[J].Acta Neuropathologica，2009，118(4)：469-474.
[8]Lovejoy CA，Li W，Reisenweber S，et al.Loss of ATRX， genome instability，and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway[J]. PLOS Genetics，2012，8(7)：e1002772.
, 百拇医药
[9]Lewis PW，Elsaesser SJ，Noh KM，et al.Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication independent chromatin assembly at telomeres[J].Proceedings of the National Academy of Sciences USA，2010，107(32)：14075-14080.
[10]Wiestler B，Capper D，Holland-Letz T，et al.ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant strocytic tumors with better prognosis[J]. Acta Neuropathologica，2013，126(3)：443-451.
, 百拇医药
[11]S.Brandner，A.von Deimling.Invited review：Diagnostic，prognostic and predictive relevance of molecular markers in gliomas[J].Neuropathology and Applied Neurobiology，2015(41)：694-720.
[12]Chamberlain MC，Born D.Prognostic significance of relative 1p 19q codeletion in oligodendroglial tumors[J].Journal of Neuro-Oncology，2015，125(2)：249-251.
[13]Hatanpaa KJ，Burma S，Zhao D，et al.Epidermal growth factor receptor in glioma：signal transduction，neuropathology，imaging， and radioresistance[J].Neoplasia，2010，12(9)：675-684., http://www.100md.com(马晓菁)
[1]Louis D N，Perry A，Reifenberger G，et al.The 2016 World Health Organization Classification of Tumors of the Central Nervous System：a summary[J].Acta Neuropathologica，2016，131(6)：803-820.
[2]Louis DN，Perry A，Burger P，et al.International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading[J].Brain Pathology，2014，24(5)：429-435.
[3]Cohen AL，Holmen SL，Colman H.IDH1 and IDH2 mutations in gliomas[J].Current Neurology&Neuroscience Reports，2013，13(5)：345.
, http://www.100md.com
[4]Appin CL，Brat DJ.Biomarker-driven diagnosis of diffuse gliomas[J].Molecular Aspects of Medicine，2015(45)：87-96.
[5]Van den Bent MJ，Dubbink HJ，Marie Y，et al.IDH1 and mutations are prognostic but not predictive for outcome in anaplastic oligodendmglial tumors：A report of the european organization for research and treatment of cancer brain tumor group[J]. Clinical Cancer Research，2010(16)：1597-1604.
[6]Metellus P，Coulibaly B，Colin C，et al.Absence of IDH mutation identifies a novel radiologic and molecular subtype of who gradeⅡ gliomas with dismal prognosis[J].Acta Neuropathologica，2010(120)：719-729.
, 百拇医药
[7]Hartmann C，Meyer J，Balss J，et al.Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age：a study of 1010 diffuse gliomas[J].Acta Neuropathologica，2009，118(4)：469-474.
[8]Lovejoy CA，Li W，Reisenweber S，et al.Loss of ATRX， genome instability，and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway[J]. PLOS Genetics，2012，8(7)：e1002772.
, 百拇医药
[9]Lewis PW，Elsaesser SJ，Noh KM，et al.Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication independent chromatin assembly at telomeres[J].Proceedings of the National Academy of Sciences USA，2010，107(32)：14075-14080.
[10]Wiestler B，Capper D，Holland-Letz T，et al.ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant strocytic tumors with better prognosis[J]. Acta Neuropathologica，2013，126(3)：443-451.
, 百拇医药
[11]S.Brandner，A.von Deimling.Invited review：Diagnostic，prognostic and predictive relevance of molecular markers in gliomas[J].Neuropathology and Applied Neurobiology，2015(41)：694-720.
[12]Chamberlain MC，Born D.Prognostic significance of relative 1p 19q codeletion in oligodendroglial tumors[J].Journal of Neuro-Oncology，2015，125(2)：249-251.
[13]Hatanpaa KJ，Burma S，Zhao D，et al.Epidermal growth factor receptor in glioma：signal transduction，neuropathology，imaging， and radioresistance[J].Neoplasia，2010，12(9)：675-684., http://www.100md.com(马晓菁)